Solasia Pharma K.K. (FRA:9SO)

Market Cap	52.64M +8.5%
Revenue (ttm)	2.33M +35.8%
Net Income	-4.76M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	0.1680
Previous Close	0.1680
Day's Range	0.1680 - 0.1680
52-Week Range	0.1320 - 0.2420
Beta	n/a
RSI	51.97
Earnings Date	May 14, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9SO

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial numbers in JPY